Electroacupuncture Shortens Postoperative Ileus After Laparoscopic Gastrectomy: Translating a Multicenter RCT into Clinical Practice

Electroacupuncture Shortens Postoperative Ileus After Laparoscopic Gastrectomy: Translating a Multicenter RCT into Clinical Practice

A multicenter randomized trial shows electroacupuncture (EA) reduces time to first flatus and defecation and lowers prolonged POI after laparoscopic gastrectomy. Mechanistic plausibility, ERAS integration, and implementation challenges are discussed with priorities for future trials.
Where Are People with Chronic Hepatitis B Lost? Global review shows major gaps after diagnosis — especially outside specialist care

Where Are People with Chronic Hepatitis B Lost? Global review shows major gaps after diagnosis — especially outside specialist care

A global systematic review (110 cohorts, 50 countries) found substantial attrition across the hepatitis B care cascade: low rates of treatment eligibility assessment and antiviral initiation in primary/community models, poor retention particularly among untreated patients, and only ~73% viral suppression on therapy in specialist settings.
Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings

Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings

An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑naïve patients and outperformed available clinical decision support tools.
Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis: Insights from the Phase 3 GLISTEN Trial and Related Studies

Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis: Insights from the Phase 3 GLISTEN Trial and Related Studies

This review synthesizes evidence from the phase 3 GLISTEN trial and preceding studies on linerixibat, an ileal bile acid transporter inhibitor, demonstrating its efficacy and safety in reducing cholestatic pruritus in primary biliary cholangitis (PBC), and its impact on patient quality of life.
Endoscopic Ultrasound–Guided Gastroenterostomy Outperforms Surgical Gastrojejunostomy for Malignant Gastric Outlet Obstruction: randomized trial shows faster recovery, shorter stay and lower costs

Endoscopic Ultrasound–Guided Gastroenterostomy Outperforms Surgical Gastrojejunostomy for Malignant Gastric Outlet Obstruction: randomized trial shows faster recovery, shorter stay and lower costs

A multicentre randomized trial found EUS-guided gastroenterostomy (EUS-GE) superior to surgical gastrojejunostomy (SGJ) for malignant gastric outlet obstruction—improving oral intake, shortening hospital stay, enhancing quality of life and reducing costs.
ENDURO trial: EUS‑guided gastroenterostomy shortens time to oral intake and matches surgery for palliation of malignant gastric outlet obstruction

ENDURO trial: EUS‑guided gastroenterostomy shortens time to oral intake and matches surgery for palliation of malignant gastric outlet obstruction

A randomized trial (ENDURO) found endoscopic ultrasound‑guided gastroenterostomy (EUS‑GE) enabled earlier resumption of solid food and was non‑inferior to surgical gastrojejunostomy for recurrent obstruction, supporting EUS‑GE as preferred palliative therapy when expertise is available.
EUS-Guided Gastroenterostomy Beats Surgical Gastrojejunostomy for Malignant Gastric Outlet Obstruction: Randomised Trial Shows Faster Diet, Shorter Stay and Lower Costs

EUS-Guided Gastroenterostomy Beats Surgical Gastrojejunostomy for Malignant Gastric Outlet Obstruction: Randomised Trial Shows Faster Diet, Shorter Stay and Lower Costs

A multicentre randomized trial (NCT05548114) found endoscopic ultrasound‑guided gastroenterostomy (EUS‑GE) superior to surgical gastrojejunostomy (SGJ) for malignant gastric outlet obstruction, with faster return to solid diet, shorter hospitalisation, better quality-of-life and lower costs.
CTNNA1 Truncating Variants Define a Moderate-Penetrance Hereditary Diffuse Gastric Cancer Spectrum — Implications for Testing, Surveillance and Risk Reduction

CTNNA1 Truncating Variants Define a Moderate-Penetrance Hereditary Diffuse Gastric Cancer Spectrum — Implications for Testing, Surveillance and Risk Reduction

Large clinical and functional study shows CTNNA1-truncating variants cause loss of αE-catenin via nonsense-mediated decay, confer substantially elevated risks of diffuse gastric cancer and lobular breast cancer versus general population but are less penetrant than CDH1 mutations; proposes simplified testing ('Porto' criteria) and clinical implications.